Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
PROK Stock Forecast 2026-2027
$2.18
Current Price
$656.69M
Market Cap
Buy 4
Hold 2
Sell 1
Wall St Analyst Ratings
Distance to PROK Price Targets
+450.5%
To High Target of $12.00
+163.8%
To Median Target of $5.75
-54.1%
To Low Target of $1.00
PROK Price Momentum
+11.8%
1 Week Change
+13.0%
1 Month Change
+175.9%
1 Year Change
-2.7%
Year-to-Date Change
-69.4%
From 52W High of $7.13
+303.7%
From 52W Low of $0.54
📊 TOP ANALYST CALLS
Did PROK Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if ProKidney is one of their latest high-conviction picks.
Latest PROK Stock Price Targets & Analyst Predictions
Based on our analysis of 12 Wall Street analysts, PROK has a bullish consensus with a median price target of $5.75 (ranging from $1.00 to $12.00). The overall analyst rating is Strong Buy (8.0/10). Currently trading at $2.18, the median forecast implies a 163.8% upside. This outlook is supported by 4 Buy, 2 Hold, and 1 Sell ratings.
The most optimistic forecast comes from Joseph Pantginis at HC Wainwright & Co., projecting a 450.5% upside. Conversely, the most conservative target is provided by Jason Gerberry at B of A Securities, suggesting a 54.1% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PROK Analyst Ratings
4
Buy
2
Hold
1
Sell
PROK Price Target Range
Low
$1.00
Average
$5.75
High
$12.00
Current: $2.18
Latest PROK Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PROK.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 16, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Initiates | $12.00 |
| Jul 15, 2025 | UBS | Eliana Merle | Buy | Maintains | $8.00 |
| Jul 14, 2025 | Guggenheim | Vamil Divan | Buy | Maintains | $7.00 |
| Jul 9, 2025 | Citigroup | Yigal Nochomovitz | Buy | Maintains | $9.00 |
| Jun 30, 2025 | B of A Securities | Jason Gerberry | Underperform | Downgrade | $1.00 |
| Sep 30, 2024 | JP Morgan | Anupam Rama | Neutral | Initiates | $N/A |
| Sep 10, 2024 | Guggenheim | Vamil Divan | Buy | Initiates | $6.00 |
| Sep 4, 2024 | B of A Securities | Jason Gerberry | Neutral | Maintains | $3.00 |
| Jun 10, 2024 | Jefferies | Kelly Shi | Buy | Maintains | $6.00 |
| May 29, 2024 | B of A Securities | Jason Gerberry | Neutral | Maintains | $4.00 |
| Mar 7, 2024 | Morgan Stanley | Judah Frommer | Equal-Weight | Assumes | $3.00 |
| Jan 2, 2024 | B of A Securities | Jason Gerberry | Neutral | Downgrade | $2.00 |
| Jul 25, 2023 | BTIG | Justin Zelin | Buy | Initiates | $16.00 |
| Dec 21, 2022 | Jefferies | Kelly Shi | Buy | Initiates | $15.00 |
| Nov 10, 2022 | Morgan Stanley | Vikram Purohit | Equal-Weight | Initiates | $13.00 |
| Oct 18, 2022 | UBS | Colin Bristow | Buy | Initiates | $18.00 |
| Oct 14, 2022 | Citigroup | Yigal Nochomovitz | Buy | Initiates | $16.00 |
| Sep 2, 2022 | Evercore ISI Group | Jonathan Miller | Outperform | Initiates | $N/A |
ProKidney Corp (PROK) Competitors
The following stocks are similar to ProKidney based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
ProKidney Corp (PROK) Financial Data
ProKidney Corp has a market capitalization of $656.69M with a P/E ratio of -4.2x. The company generates $893,000 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is +196.1% quarter-over-quarter, while maintaining an operating margin of -20,306.2% and return on equity of -43.2%.
Valuation Metrics
Market Cap
$656.69M
Enterprise Value
$1.32B
P/E Ratio
-4.2x
PEG Ratio
-3.0x
Price/Sales
735.4x
Growth & Margins
Revenue Growth (YoY)
+196.1%
Gross Margin
N/A
Operating Margin
-20,306.2%
Net Margin
0.0%
EPS Growth
+196.1%
Financial Health
Cash/Price Ratio
+87.2%
Current Ratio
9.1x
Debt/Equity
1.3x
ROE
-43.2%
ROA
-26.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
ProKidney Corp (PROK) Business Model
About ProKidney Corp
What They Do
Develops cell therapy solutions for kidney disease.
Business Model
ProKidney Corp operates by developing innovative regenerative medicine therapies specifically targeting chronic kidney disease (CKD). The company generates revenue through the advancement of its flagship product, REACT, which is an autologous cell therapy designed to repair kidney tissues. By collaborating with healthcare institutions and participating in clinical trials, ProKidney aims to bring its solutions to market, addressing the significant healthcare costs associated with CKD management.
Additional Information
As CKD poses a major global health challenge, ProKidney's work is critical in potentially reducing the reliance on dialysis and kidney transplants. The company is positioned in a rapidly evolving biotechnology sector, focusing on improving patient outcomes while addressing unmet medical needs in kidney disease treatment.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
231
CEO
Dr. Bruce Culleton M.D.
Country
United States
IPO Year
2022
Website
prokidney.comProKidney Corp (PROK) Latest News & Analysis
Latest News
ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer
25 days ago
Quick Summary
ProKidney Corp. (Nasdaq: PROK) has appointed Greg Madison as Chief Commercial Officer, enhancing its leadership as it focuses on chronic kidney disease therapies.
Why It Matters
The appointment of a Chief Commercial Officer signals ProKidney's commitment to commercializing its therapies, potentially boosting growth and investor confidence in its future market performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
PROK's key asset, Rilparencel, is in a pivotal trial (PROACT 1). The FDA accepted eGFR slope analysis for potential accelerated approval, with topline results expected by Q2 2027.
Why It Matters
The clear regulatory pathway for Rilparencel and the upcoming topline data by Q2 2027 could significantly impact PROK's valuation and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Positive
ProKidney Corp. (PROK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
3 months ago
Quick Summary
ProKidney Corp. (PROK) presented at the 44th Annual J.P. Morgan Healthcare Conference, highlighting developments and insights relevant for investors in the healthcare sector.
Why It Matters
ProKidney's presentation at a major healthcare conference signals potential investor interest and updates on its pipeline, influencing stock performance and market perception.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
ProKidney Corp. (Nasdaq: PROK) will present at the J.P. Morgan Healthcare Conference, with CEO Bruce Culleton leading the presentation and management hosting one-on-one meetings.
Why It Matters
ProKidney's presentation at a major healthcare conference could boost visibility and investor confidence, potentially impacting stock performance and attracting new partnerships or funding.
Source: GlobeNewsWire
Market Sentiment:
Neutral
ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates
5 months ago
Quick Summary
ProKidney Corp. (Nasdaq: PROK) reported its Q3 2025 financial results and updates on regulatory and clinical progress in chronic kidney disease therapies.
Why It Matters
ProKidney's financial results and updates on clinical progress may impact stock performance, reflecting investor sentiment on its prospects in the chronic kidney disease market.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
ProKidney Corp. presented full Phase 2 REGEN-007 trial results for rilparencel, showing its potential to preserve kidney function in advanced CKD patients with diabetes at ASN Kidney Week 2025.
Why It Matters
Positive Phase 2 trial results for ProKidney's rilparencel indicate strong potential in treating advanced CKD, which could boost the company's stock value and attract investor interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About PROK Stock
What is ProKidney Corp's (PROK) stock forecast for 2026?
Based on our analysis of 12 Wall Street analysts, ProKidney Corp (PROK) has a median price target of $5.75. The highest price target is $12.00 and the lowest is $1.00.
Is PROK stock a good investment in 2026?
According to current analyst ratings, PROK has 4 Buy ratings, 2 Hold ratings, and 1 Sell ratings. The stock is currently trading at $2.18. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PROK stock?
Wall Street analysts predict PROK stock could reach $5.75 in the next 12 months. This represents a 163.8% increase from the current price of $2.18. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is ProKidney Corp's business model?
ProKidney Corp operates by developing innovative regenerative medicine therapies specifically targeting chronic kidney disease (CKD). The company generates revenue through the advancement of its flagship product, REACT, which is an autologous cell therapy designed to repair kidney tissues. By collaborating with healthcare institutions and participating in clinical trials, ProKidney aims to bring its solutions to market, addressing the significant healthcare costs associated with CKD management.
What is the highest forecasted price for PROK ProKidney Corp?
The highest price target for PROK is $12.00 from Joseph Pantginis at HC Wainwright & Co., which represents a 450.5% increase from the current price of $2.18.
What is the lowest forecasted price for PROK ProKidney Corp?
The lowest price target for PROK is $1.00 from Jason Gerberry at B of A Securities, which represents a -54.1% decrease from the current price of $2.18.
What is the overall PROK consensus from analysts for ProKidney Corp?
The overall analyst consensus for PROK is bullish. Out of 12 Wall Street analysts, 4 rate it as Buy, 2 as Hold, and 1 as Sell, with a median price target of $5.75.
How accurate are PROK stock price projections?
Stock price projections, including those for ProKidney Corp, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 19, 2026 7:33 PM UTC